Emcure Pharmaceuticals (Emcure Pharma) IPO: Unlocking the IPO in Detail

Emcure Pharma IPO is open for subscription starting Wednesday, July 3, 2024, and closing on Friday, July 5, 2024. The price is decided at Rs 960 to Rs 1008 per share. The minimum lot size for the retail category is 14 shares. The minimum lot size for small NII is 15 lots consisting of 210 shares. Meanwhile, the minimum lot for big non-institutional investors is 71 lots with 994 shares. The minimum investment required for retail category investors is Rs 14,112 (1008 x 14 shares). However, for small non-institutional investors, the minimum investment amount required is Rs 2,11,680 (1008 x 210 shares); for big non-institutional investors, it is Rs 10,01,952 (1008 x 994 shares). Emcure Pharma IPO is a book-built issue of Rs 1952.03 crores. This issue is a combination of fresh issue and offer-for-sale. The fresh issue is of 0.79 crore equity shares amounting to Rs 800 crores and OFS is of 1.14 crore equity shares amounting to Rs 1,152.03 crores. The allotment for this IPO is expected to be finalised on Monday, July 8, 2024. Emcure Pharma Limited IPO will be listed on both BSE and NSE, and the listing date is fixed on Wednesday, July 10, 2024. The book-running lead managers of Emcure Pharma Limited are Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P. Morgan India Private Ltd and Jefferies India Private Limited. The registrar for this new IPO is Link Intime India Private Limited.

Also Read | SEBI Revises Eligibility Criteria for Derivatives Market Stocks

About Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited incorporated in 1981, is an Indian pharmaceutical company that develops and manufactures a wide range of pharma products across several major therapeutic areas. The company has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances. Emcure has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023. Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files. Emcure’s marketing and distribution network in India was supported by over 5,000 field personnel who regularly interact with healthcare providers. 

Objectives of Emcure Pharma IPO

The amount received from this IPO will be used to repay or prepay certain loans availed by the company, meet the day-to-day capital needs, and for general corporate purposes. 

Financials of Emcure Pharmaceuticals Limited (Amt in Rs Crore)

Emcure Pharma reported a revenue of Rs 6,715.16 crore and net profit of Rs 527.58 crore for the period ending on 31 Mar 2024. The company’s revenue increased by 11.33 and PAT dropped by -6.1% between the FY ending on 31st March 2024 and 31st March 2023. 

Other Important Details of Emcure Pharmaceuticals Limited IPO

Time-Table of Emcure Pharmaceuticals Limited IPO

Lot Size of Emcure Pharma Limited IPO

IPO Reservation of Emcure Pharma Limited

Promoters of Emcure Pharma Limited and Their Holdings

The promoters of Emcure Pharma company are Satish Mehta and Sunil Mehta. 

Key Performance Indicator of Emcure Pharma Limited IPO

EPS and P/E Ratio Post IPO

The book-running lead managers of Emcure Pharma Limited are Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited and Jefferies India Private Limited. 

How do you apply for the Emcure Pharma Limited IPO?

Wait for the public issue to open for subscription, then visit Bigul website to apply for the Emcure Pharma Limited IPO with Bigul.

How do you check the allotment status of the Emcure Pharma Limited IPO?

The registrar for Emcure Pharma Limited IPO is Link Intime India Private Limited. To check your allotment status, please click here.

FAQs

1. What are the details of Emcure Pharma Limited IPO 2024?

Emcure Pharma IPO is a book-built issue of Rs 1952.03 crores. This issue is a combination of fresh issue and offer-for-sale. The fresh issue is of 0.79 crore equity shares amounting to Rs 800 crores and OFS is of 1.14 crore equity shares amounting to Rs 1,152.03 crores.

2. Who are the lead managers for the Emcure Pharma Limited IPO?

Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P. Morgan India Private Ltd and Jefferies India Private Limited are appointed as the lead managers for this IPO.

3. What is the role of Link Intime India in this IPO?

Link Intime India Limited is the registrar for Emcure Pharma Limited, handling the IPO's administrative aspects.

4. How can I apply for the Emcure Pharma Limited IPO?

The public subscription of this IPO will open on July 3, 2024. Click here to continue the application process.

5. How will the net proceeds from the IPO be utilised?

The amount received from this IPO will be used for repayment or prepayment of certain loans availed by the company. Additionally to meet the day-to-day capital needs and general corporate purposes.

6. How can I check the allotment status of the IPO?

Investors can check out the allotment status of the Emcure Pharma Limited IPO 2024 by visiting here.

7. What is the financial performance of Emcure Pharma Limited?

Emcure Pharma reported a revenue of Rs 6,715.16 crore and net profit of Rs 527.58 crore for the period ending on 31 Mar 2024. The company’s revenue increased by 11.33 and PAT dropped by -6.1% between the FY ending on 31st March 2024 and 31st March 2023. 

Also Read | Quant Mutual Fund: Investors Redeemed Rs 1400 Crore in 3 Days